S
7.30
-0.44 (-5.68%)
| Previous Close | 7.74 |
| Open | 7.75 |
| Volume | 14,204 |
| Avg. Volume (3M) | 160,380 |
| Market Cap | 21,561,782 |
| Price / Sales | 1.39 |
| Price / Book | 0.470 |
| 52 Weeks Range | |
| Earnings Date | 19 May 2025 - 23 May 2025 |
| Profit Margin | -81.75% |
| Operating Margin (TTM) | -15.44% |
| Diluted EPS (TTM) | -0.340 |
| Quarterly Revenue Growth (YOY) | 2,416.90% |
| Total Debt/Equity (MRQ) | 3.76% |
| Current Ratio (MRQ) | 5.81 |
| Operating Cash Flow (TTM) | -17.02 M |
| Levered Free Cash Flow (TTM) | -12.43 M |
| Return on Assets (TTM) | -15.24% |
| Return on Equity (TTM) | -24.59% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Sol-Gel Technologies Ltd. | Mixed | Bearish |
AIStockmoo Score
0.0
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 0.00 |
|
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline consists of silica-based microencapsulation technology platform, and several generic product candidates across multiple indications. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 65.17% |
| % Held by Institutions | 24.02% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Migdal Insurance & Financial Holdings Ltd. | 31 Mar 2025 | 122,755 |
| Harel Insurance Investments & Financial Services Ltd. | 31 Mar 2025 | 92,033 |
| Yelin Lapidot Holdings Management Ltd. | 31 Mar 2025 | 22,708 |
| Menora Mivtachim Holdings Ltd. | 31 Dec 2024 | 7,611 |
| Bnp Paribas Financial Markets | 31 Dec 2024 | 3,950 |
| Caliber Wealth Management, Llc / Ks | 31 Mar 2025 | 1,300 |
| Steward Partners Investment Advisory, Llc | 31 Dec 2024 | 516 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 01 May 2025 | Announcement | Sol-Gel Announces Reverse Share Split |
| 17 Apr 2025 | Announcement | Sol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY® and TWYNEO® in the U.S. |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |